Raymond James & Associates Supernus Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	BUY	$34.93 - $42.03 $365,856 - $440,222	10,474 New	10,474 $379,000
Q3 2021 Nov 02, 2021	SELL	$23.54 - $31.39 $229,632 - $306,209	-9,755 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$26.72 - $33.19 $114,388 - $142,086	-4,281 Reduced 30.5%	9,755 $300,000
Q1 2021 May 14, 2021	SELL	$24.15 - $31.45 $148,691 - $193,637	-6,157 Reduced 30.49%	14,036 $367,000
Q4 2020 Feb 12, 2021	SELL	$17.7 - $25.81 $4,849 - $7,071	-274 Reduced 1.34%	20,193 $508,000
Q3 2020 Nov 04, 2020	BUY	$20.2 - $25.05 $43,228 - $53,607	2,140 Added 11.68%	20,467 $427,000
Q2 2020 Jul 28, 2020	SELL	$17.09 - $24.89 $100,181 - $145,905	-5,862 Reduced 24.23%	18,327 $435,000
Q1 2020 Apr 21, 2020	BUY	$14.45 - $24.69 $10,201 - $17,431	706 Added 3.01%	24,189 $435,000
Q4 2019 Feb 12, 2020	SELL	$19.93 - $29.13 $556,565 - $813,484	-27,926 Reduced 54.32%	23,483 $557,000
Q3 2019 Nov 07, 2019	BUY	$25.47 - $33.37 $144,313 - $189,074	5,666 Added 12.39%	51,409 $1.41 Million
Q2 2019 Aug 06, 2019	BUY	$29.96 - $38.87 $68,039 - $88,273	2,271 Added 5.22%	45,743 $1.51 Million
Q1 2019 May 06, 2019	SELL	$32.77 - $41.99 $83,956 - $107,578	-2,562 Reduced 5.57%	43,472 $1.52 Million
Q4 2018 Feb 11, 2019	BUY	$30.84 - $49.51 $1.14 Million - $1.83 Million	36,942 Added 406.31%	46,034 $1.53 Million
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $52,392 - $69,386	-1,227 Reduced 11.89%	9,092 $458,000
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $68,663 - $93,186	1,557 Added 17.77%	10,319 $618,000
Q1 2018 May 14, 2018	BUY	$37.15 - $46.9 $58,325 - $73,633	1,570 Added 21.83%	8,762 $401,000
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $82,336 - $96,361	-2,262 Reduced 23.93%	7,192 $287,000
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $51,303 - $69,311	1,396 Added 17.32%	9,454 $378,000
Q2 2017 Aug 14, 2017	BUY	N/A	8,058	8,058 $347,000

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$376 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$222 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$185 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$104 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$95.3 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account